188 related articles for article (PubMed ID: 16556667)
1. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.
Turner GB; Johnston BT; McCance DR; McGinty A; Watson RG; Patterson CC; Ardill JE
Gut; 2006 Nov; 55(11):1586-91. PubMed ID: 16556667
[TBL] [Abstract][Full Text] [Related]
2. Description of patients with midgut carcinoid tumours: clinical database from a Danish centre.
Nykjaer KM; Grønbaek H; Nielsen DT; Christiansen P; Astrup LB
In Vivo; 2007; 21(4):679-84. PubMed ID: 17708366
[TBL] [Abstract][Full Text] [Related]
3. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
4. Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours.
van der Horst-Schrivers AN; Post WJ; Kema IP; Links TP; Willemse PH; Wymenga AN; de Vries EG
Eur J Cancer; 2007 Dec; 43(18):2651-7. PubMed ID: 17825550
[TBL] [Abstract][Full Text] [Related]
5. A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours.
Stronge RL; Turner GB; Johnston BT; McCance DR; McGinty A; Patterson CC; Ardill JE
Ann Clin Biochem; 2008 Nov; 45(Pt 6):560-6. PubMed ID: 18782815
[TBL] [Abstract][Full Text] [Related]
6. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases.
Hellman P; Lundström T; Ohrvall U; Eriksson B; Skogseid B; Oberg K; Tiensuu Janson E; Akerström G
World J Surg; 2002 Aug; 26(8):991-7. PubMed ID: 12016480
[TBL] [Abstract][Full Text] [Related]
7. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
[TBL] [Abstract][Full Text] [Related]
8. Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome.
Swärd C; Johanson V; Nieveen van Dijkum E; Jansson S; Nilsson O; Wängberg B; Ahlman H; Kölby L
Br J Surg; 2009 May; 96(5):517-21. PubMed ID: 19358175
[TBL] [Abstract][Full Text] [Related]
9. Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome).
de Herder WW
Best Pract Res Clin Gastroenterol; 2005 Oct; 19(5):705-15. PubMed ID: 16253895
[TBL] [Abstract][Full Text] [Related]
10. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
Kölby L; Persson G; Franzén S; Ahrén B
Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
[TBL] [Abstract][Full Text] [Related]
11. [Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin-A for clinical follow-up].
Igaz P; Rácz K; Tulassay Z
Orv Hetil; 2007 Dec; 148(49):2343-6. PubMed ID: 18048114
[TBL] [Abstract][Full Text] [Related]
12. Biochemical diagnosis of neuroendocrine GEP tumor.
Oberg K
Yale J Biol Med; 1997; 70(5-6):501-8. PubMed ID: 9825477
[TBL] [Abstract][Full Text] [Related]
13. Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung.
García-Yuste M; Matilla JM; Cueto A; Paniagua JM; Ramos G; Cañizares MA; Muguruza I;
Eur J Cardiothorac Surg; 2007 Feb; 31(2):192-7. PubMed ID: 17196822
[TBL] [Abstract][Full Text] [Related]
14. Management of midgut carcinoids.
Akerström G; Hellman P; Hessman O; Osmak L
J Surg Oncol; 2005 Mar; 89(3):161-9. PubMed ID: 15719373
[TBL] [Abstract][Full Text] [Related]
15. Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis.
Cunningham JL; Grimelius L; Sundin A; Agarwal S; Janson ET
Acta Oncol; 2007; 46(6):747-56. PubMed ID: 17653896
[TBL] [Abstract][Full Text] [Related]
16. Metastatic carcinoid tumor: changing patterns of care over two decades.
Townsend A; Price T; Yeend S; Pittman K; Patterson K; Luke C
J Clin Gastroenterol; 2010 Mar; 44(3):195-9. PubMed ID: 19609217
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary atypical carcinoid: predictors of survival in 106 cases.
Beasley MB; Thunnissen FB; Brambilla E; Hasleton P; Steele R; Hammar SP; Colby TV; Sheppard M; Shimosato Y; Koss MN; Falk R; Travis WD
Hum Pathol; 2000 Oct; 31(10):1255-65. PubMed ID: 11070119
[TBL] [Abstract][Full Text] [Related]
18. Comparison of survival between malignant neuroendocrine tumours of midgut and pancreatic origin.
Johanson V; Tisell LE; Olbe L; Wängberg B; Nilsson O; Ahlman H
Br J Cancer; 1999 Jun; 80(8):1259-61. PubMed ID: 10376980
[TBL] [Abstract][Full Text] [Related]
19. Neurokinin A levels predict survival in patients with stage IV well differentiated small bowel neuroendocrine neoplasms.
Diebold AE; Boudreaux JP; Wang YZ; Anthony LB; Uhlhorn AP; Ryan P; Mamikunian P; Mamikunian G; Woltering EA
Surgery; 2012 Dec; 152(6):1172-6. PubMed ID: 23102678
[TBL] [Abstract][Full Text] [Related]
20. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
